Evidence map›Paper›PMID 31686349›Full record

ArticleInternational journal of hematology2020

Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma.

Yosuke Matsumoto, Yoshiaki Chinen, Yuji Shimura, Hisao Nagoshi, Nana Sasaki, Ayako Muramatsu, Kodai Kuriyama, Muneo Ohshiro, Yoshiko Hirakawa, Toshiki Iwai and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Evolutionary Restructuring and Systematic Review of theJournal of developmental biology · 2026
    Review
  3. Article
  4. Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Yosuke MatsumotoDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto, 605-8981, Japan. yosuke-m@koto.kpu-m.ac.jp.ORCID http://orcid.org/0000-0001-7416-3222
Yoshiaki ChinenDepartment of Hematology, Fukuchiyama City Hospital, Fukuchiyama, Japan.
Yuji ShimuraDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hisao NagoshiDepartment of Hematology and Oncology, Hiroshima University, Hiroshima, Japan.
Nana SasakiDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Ayako MuramatsuDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto, 605-8981, Japan.
Kodai KuriyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto, 605-8981, Japan.
Muneo OhshiroDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto, 605-8981, Japan.
Yoshiko HirakawaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto, 605-8981, Japan.
Toshiki IwaiDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto, 605-8981, Japan.
Hitoji UchiyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto, 605-8981, Japan.
Tomohiko TakiDepartment of Medical Technology, Kyorin University, Faculty of Health Science, Tokyo, Japan.
Shigeo HoriikeDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Masafumi TaniwakiCenter for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kyoto first Red Cross hospital · JPKyoto Prefectural University of Medicine · JPHiroshima University · JPJapanese Red Cross Society Kyoto Daini Hospital · JPKyorin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expression of intragenic exon rearrangements (IERs) has reportedly been detected in both normal and cancer cells. However, there have been few reports of occurrence of these rearrangements specific to neoplasms including malignant lymphoma. In this study, we detected IERs of ten genes (NBPF8, SOBP, AUTS2, RAB21, SPATA13, ABCC4, WDR7, PHLPP1, NFATC1 and MAGED1) in non-Hodgkin B cell lymphoma (B-NHL) cell line KPUM-UH1 using a high-resolution single nucleotide polymorphism array and reverse transcription polymerase chain reaction using reversely directed divergent primers within exons involved in genomic intragenic gains followed by sequencing analysis. Among them, the IERs involved in SOBP (6q21) exon 2 and 3 and AUTS2 (7q11.22) exon 2-4 were the molecular lesions specific to tumors and were frequently detected in B-NHL samples. These IERs constitute novel genetic alterations of B-NHL, which might be associated with tumorigenesis and be useful as genetic biological markers.

Indexed as

Biomarkers, TumorCarrier ProteinsCell Line, TumorCytoskeletal ProteinsExonsHumansLeukocytes, MononuclearLymphoma, B-CellLymphoma, Non-HodgkinNeoplasm ProteinsNuclear ProteinsPolymerase Chain ReactionPolymorphism, Single NucleotideTranscription FactorsAUTS2 protein, humanBiomarkers, TumorCarrier ProteinsCytoskeletal ProteinsNeoplasm ProteinsNuclear ProteinsSOBP protein, humanTranscription FactorsAUTS2Intragenic exon rearrangementLymphomaSOBP

Identifiers

PMID31686349
OpenAlexW2987242786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.